Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway

Fig. 3

The combination of trastuzumab and glycolysis inhibitors results in a synergistic effect. a Western blot analysis of protein extracts from NCI-N87 and MKN45 cells 72 h after treated by Ttzm (40 μg/ml). GAPDH was used as a loading control. b Western blot analysis of MACC1, HK2, and LDHA expression in NCI-N87 and MKN45 parental cells and trastuzumab-resistant cells NCI-N87/TR and MKN45/TR. GAPDH was used as a loading control. c Percentage of glucose uptake (red) and lactate production (blue) of NCI-N87and MKN45 cells, 24, 48, and 72 h after Ttzm treatment at different concentrations. Data represent mean ± SD of triplicate experiments. Results are statistically significant for all the drugs vs. control by one-way ANOVA.*P < 0.05, # P < 0.01, + P < 0.001. d NCI-N87 and MKN45 parental (upper) and trastuzumab-resistant cells (below) were seeded in 96-well plates at 3 × 103 cells/well. After 24 h, cells were treated with the indicated concentration of Ttzm, 2-deoxyglucose (2-DG), oxamate (OX), or Ttzm plus 2-DG/OX, incubated for 72 h and cell viability was determined. (The concentration of Ttam, 2-DG, and OX was represented in the Additional file 2: Table S3). Representative data are presented as the percentage of viability inhibition measured in cells not treated with Ttzm nor 2-DG/OX. Data represent mean ± SD of triplicate experiments,*P < 0.05, # P < 0.01, + P < 0.001. S, synergy (CI < 1.0). e Combination index (CI) for experimental values of cell viability inhibition by Ttzm plus 2-DG/OX in NCI-N87 and MKN45 parental cells and trastuzumab-resistant cells, as measured by Chou and Talalay method

Back to article page